



CRISPR gene editing rescues deficits in human *USH2A* mutant retinal organoids

Nejmi Dilmac, Naqi Haider, Brian Desrosiers, Rithu Pattali, Shengfang Jin, Charles Albright
Editas Medicine, Inc., Cambridge, MA, USA

ARVO Annual Meeting 2021

1

Disclosures

- Employees and shareholders of Editas Medicine: N.D., R.P., S.J.
- Former employees of Editas Medicine: N.H., B.D., C.A.


2

Introduction

Background

- USH2A, a retinal degenerative disease leading to hearing and vision loss, is most commonly caused by recessive mutations in exon 13 of the *USH2A* gene encoding the USH2A protein
- USH2A protein is localized in the connecting cilium between inner and outer segments of photoreceptors, and supports inner/outer segment formation and photoreceptor morphology

USH2 protein complex



USH2A, Usher syndrome type II

3 © 2021 Editas Medicine


3

Objective

Objective

- To investigate whether deleting or inverting *USH2A* exon 13 could restore deficits caused by mutations at this site in a novel induced pluripotent stem cell (iPSC)-derived retinal organoid model

CRISPR-Cas9 editing of *USH2A* exon 13




RNP, ribonucleotide protein

4 © 2021 Editas Medicine

4


Methods



5


Edited iPSC clones successfully differentiated to retinal organoids

10X images at Day 100



6

Retinal organoids derived from iPSCs demonstrated time-dependent expression of developmental genes




Expression patterns of retinal markers in retinal organoids are consistent with temporal gene regulation during retinal development *in vivo*

Crx, cone rod homeobox (cone-specific transcription factor); DAPI, 4',6-diamidino-2-phenylindole (nuclei marker); L/M opsin, long- and middle-wavelength sensitive opsin; Nrl, neural retina leucine zipper (rod-specific transcription factor)
 Note: different batches of organoids used for RT-qPCR and IHC
 Hoshino, et al. Dev Cell 2017
 Mellough, et al. Development 2019
 7 © 2021 Editas Medicine

7

USH2A exon 13 is absent from retinal organoids derived from edited iPSCs

RT-qPCR at Days 70/76 and 110




USH2A transcripts were detected in retinal organoids from Day 70 and stayed stable after that

8 © 2021 Editas Medicine

8

***USH2A* Δ13 deletion organoids had similar photoreceptor extensions to healthy controls**

20X images at Day 215




The mutant organoids had shorter and less dense extensions than healthy control or *USH2A* Δ13 deletion organoids, with disorganized structure

9

***USH2A* Δ13 deletion retinal organoids had restored *USH2A* protein expression**


20X images at Day 215



10

***USH2A* Δ 13 deletion retinal organoids showed highly organized photoreceptor morphology, similar to that of healthy controls**

20X images at Day 215




11 © 2021 Editas Medicine

11

***USH2A* protein complex, with VLGR1 and whirlin, was restored in *USH2A* Δ 13 deletion organoids**

20X images at Day 215



12 © 2021 Editas Medicine

12

Conclusions

Retinal organoids derived from iPSCs **provide a robust and viable model to study human retinal development** *ex vivo*

This proof-of-concept study demonstrated that CRISPR-edited *USH2A* exon 13 deletion **restored USH2 protein complex expression** and **rescued deficits in photoreceptor morphology** in **human retinal organoids** for the first time

These results support using *USH2A* exon 13 deletion as a **therapeutic strategy for the treatment of *USH2A*-associated retinal degenerative diseases**

13 © 2021 Editas Medicine

13

Acknowledgments

- The authors would like to thank all of their Editas colleagues for helping to plan, perform, analyze, and present this work
- The authors gratefully acknowledge Dr. Eric Pierce and Dr. Qin Liu from the Massachusetts Eye and Ear Institute (MEEI) for providing peripheral blood mononuclear cells from a patient with *USH2A*, which were used in the research presented here in the form of iPSCs
- Editorial assistance was provided by Hilary Wong, PhD, of 2 the Nth (Cheshire, UK) and was funded by Editas Medicine

14 © 2021 Editas Medicine

14